| 1 |
Su J, Brunner L, Ates Oz E, Sacherl J, Frank G, Kerth HA, Thiele F, Wiegand M, Mogler C, Aguilar JC, Knolle PA, Collin N, Kosinska AD, Protzer U. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J Hepatol 2023;78:717-30. [PMID: 36634821 DOI: 10.1016/j.jhep.2022.12.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Wang Z, Wang X, Jin R, Liu F, Rao H, Wei L, Chen H, Feng B. LAMP3 expression in the liver is involved in T cell activation and adaptive immune regulation in hepatitis B virus infection. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1127572] [Reference Citation Analysis]
|
| 3 |
Svicher V, Salpini R, D’anna S, Piermatteo L, Iannetta M, Malagnino V, Sarmati L. New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1143258] [Reference Citation Analysis]
|
| 4 |
Zaiets I, Gunewardena S, Menne S, Weinman SA, Gudima SO. Sera of Individuals Chronically Infected with Hepatitis B Virus (HBV) Contain Diverse RNA Types Produced by HBV Replication or Derived from Integrated HBV DNA. J Virol 2023;:e0195022. [PMID: 36877036 DOI: 10.1128/jvi.01950-22] [Reference Citation Analysis]
|
| 5 |
Sun X, Fu H, Wang C, Zhang Y, Han W, Chen H, Wang Y, Chen Q, He Y, Huang Q, Yan C, Chen Y, Han T, Lv M, Mo X, Wang J, Wang F, Chen Y, Zhu X, Xu L, Liu K, Huang X, Zhang X. Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection. Bone Marrow Transplant 2023;58:265-72. [PMID: 36456810 DOI: 10.1038/s41409-022-01880-7] [Reference Citation Analysis]
|
| 6 |
Steve RJ, Prakash A, Ponnuvel S, Dickson CJ, Nandan K, Singh B, Sam GA, Goel A, Zachariah UG, Eapen CE, Kannangai R, Abraham P, Fletcher GJ. Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection. J Clin Virol 2023;160:105378. [PMID: 36641983 DOI: 10.1016/j.jcv.2023.105378] [Reference Citation Analysis]
|
| 7 |
Zhang H, Xu Z, Gao H, Zhang Q. Systematic analysis on the mechanism of Zhizi-Bopi decoction against hepatitis B via network pharmacology and molecular docking. Biotechnol Lett 2023. [PMID: 36807721 DOI: 10.1007/s10529-023-03359-x] [Reference Citation Analysis]
|
| 8 |
Freeland C, Cohen C. The impact of a hepatitis B diagnosis. Gastrointestinal Nursing 2023;21:S8-S10. [DOI: 10.12968/gasn.2023.21.sup1.s8] [Reference Citation Analysis]
|
| 9 |
El Messaoudi S, Lemenuel-Diot A, Gonçalves A, Guedj J. A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon. Clin Pharmacol Ther 2023;113:390-400. [PMID: 36408671 DOI: 10.1002/cpt.2798] [Reference Citation Analysis]
|
| 10 |
Li H, Niu X, Zhang Y, Zhang D, Zhang Y, Wang L, Miao Y, Jiang Y, Ji J, Chen Q, Wu X, Ediage EN, Kakuda TN, Biermer M. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev 2023;12:175-80. [PMID: 36415122 DOI: 10.1002/cpdd.1197] [Reference Citation Analysis]
|
| 11 |
Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, Janczewska E, Nahass RG, Bourgeois S, Buti M, Lampertico P, Lenz O, Verbinnen T, Vandenbossche J, Talloen W, Kalmeijer R, Beumont M, Biermer M, Shukla U. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut 2023:gutjnl-2022-328041. [PMID: 36697207 DOI: 10.1136/gutjnl-2022-328041] [Reference Citation Analysis]
|
| 12 |
Wu F, Wang Y, Cui D, Tian Y, Lu R, Liu C, Li M, Li Y, Gao N, Jiang Z, Li X, Zhai S, Zhang X, Jia X, Dang S. Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens. J Clin Med 2023;12. [PMID: 36615161 DOI: 10.3390/jcm12010361] [Reference Citation Analysis]
|
| 13 |
Inoue T, Tanaka Y. Noninvasive assessments of liver disease severity based on biomarkers. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00009-4] [Reference Citation Analysis]
|
| 14 |
Önlen Güneri C, Okuyan HM, Gülbol Duran G, Demir M. Investigation of LncRNAs expression in patients with hepatitis B virus. J CLIN MED KAZ 2022;19:27-31. [DOI: 10.23950/jcmk/12662] [Reference Citation Analysis]
|
| 15 |
Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, Liu Z, Li Y, Zuo S, Lu Y. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Hepatol Int 2022. [PMID: 36580258 DOI: 10.1007/s12072-022-10450-4] [Reference Citation Analysis]
|
| 16 |
Sausen DG, Shechter O, Bietsch W, Shi Z, Miller SM, Gallo ES, Dahari H, Borenstein R. Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus. Int J Mol Sci 2022;23. [PMID: 36555623 DOI: 10.3390/ijms232415973] [Reference Citation Analysis]
|
| 17 |
Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY, Hu TH. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses 2022;14. [PMID: 36560675 DOI: 10.3390/v14122671] [Reference Citation Analysis]
|
| 18 |
Wallace J, Richmond J, Howell J, Hajarizadeh B, Power J, Treloar C, Revill PA, Cowie B, Wang S, Stoové M, Pedrana A, Hellard M. Exploring the Public Health and Social Implications of Future Curative Hepatitis B Interventions. Viruses 2022;14. [PMID: 36423153 DOI: 10.3390/v14112542] [Reference Citation Analysis]
|
| 19 |
Yao H, Li P, Xin J, Liang X, Jiang J, Shi D, Li J, Hassan HM, Chen X, Li J. MiRNA/mRNA network topology in hepatitis virus B-related liver cirrhosis reveals miR-20a-5p/340-5p as hubs initiating fibrosis. BMC Med Genomics 2022;15:240. [DOI: 10.1186/s12920-022-01390-x] [Reference Citation Analysis]
|
| 20 |
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J Hepatol 2022;77:1265-75. [PMID: 35697332 DOI: 10.1016/j.jhep.2022.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 21 |
Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Ka-Ho Wong D, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol 2022;77:1287-98. [PMID: 35870702 DOI: 10.1016/j.jhep.2022.07.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 22 |
Jhajharia S, Lai F, Low HB, Purushotorman K, Shunmuganathan BD, Chan CEZ, Hammond R, Netter HJ, Chen Q, Lim SG, MacAry PA. Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus. NPJ Vaccines 2022;7:121. [PMID: 36271019 DOI: 10.1038/s41541-022-00516-7] [Reference Citation Analysis]
|
| 23 |
Pham TN, Le DH, Dao DV, Phan LT, Pham TT, Nguyen TB, Mize GW, Gish RG, Lee WM, Trang A, Le AN, Chen M, Phan HT, Nguyen BT, Tang HK, Dao DY. Establishing baseline framework for hepatitis B virus micro-elimination in Ho Chi Minh City, Vietnam – A community-based seroprevalence study. The Lancet Regional Health - Western Pacific 2022. [DOI: 10.1016/j.lanwpc.2022.100620] [Reference Citation Analysis]
|
| 24 |
Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan JY, Lim SG, Tanaka Y, Xie W, Yoon JH, Duan Z, Kurosaki M, Park SJ, Labio ME, Kumar R, Kweon YO, Yim HJ, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell FM, Paff M, Theodore D. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol 2022;77:967-77. [PMID: 35714812 DOI: 10.1016/j.jhep.2022.05.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 25 |
Moskaliuk V, Rudan I. INVESTIGATIONS OF CHRONIC HEPATITIS B and C IN HIV-INFECTION. Med Sci of Ukr 2022;18:29-34. [DOI: 10.32345/2664-4738.3.2022.04] [Reference Citation Analysis]
|
| 26 |
Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, Liu Z, Li Y, Zuo S, Lu Y. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitorsComparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.. [DOI: 10.21203/rs.3.rs-2069277/v1] [Reference Citation Analysis]
|
| 27 |
Ghany MG, Lok AS. Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA. Journal of Clinical Investigation 2022;132:e163175. [DOI: 10.1172/jci163175] [Reference Citation Analysis]
|
| 28 |
Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, Toyoda H, Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. Hepatol Int 2022. [PMID: 36070123 DOI: 10.1007/s12072-022-10411-x] [Reference Citation Analysis]
|
| 29 |
Yao N, Wang J, Wu Y, Zhu Y, Feng Y, Fu S, Liu J, Yang Y, Zhao Y, Shi L, Yang N, Chen T. Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: An opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B. J Viral Hepat 2022;29:748-55. [PMID: 35722733 DOI: 10.1111/jvh.13720] [Reference Citation Analysis]
|
| 30 |
Zhao ZM, Zhu CW, Huang JQ, Li XD, Zhang YX, Liang J, Zhang W, Zhang Y, Jiang XG, Zong YL, Zhang KJ, Sun KW, Zhang B, Lv YH, Xing HC, Xie Q, Liu P, Liu CH. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial. J Ethnopharmacol 2022;:115599. [PMID: 35932973 DOI: 10.1016/j.jep.2022.115599] [Reference Citation Analysis]
|
| 31 |
Duraisamy GS, Jo E, Huvarova I, Park KP, Heger Z, Adam V, Růžek D, Windisch MP, Miller AD. Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion. Heliyon 2022. [DOI: 10.1016/j.heliyon.2022.e10465] [Reference Citation Analysis]
|
| 32 |
Gao Z, Shen Z, Wu J, Song Y, Liu N, Deng Q, Xie Y, Liu J. Interleukin-33 mediates both immune-related and non-immune-related inhibitory effects against hepatitis B virus. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 33 |
Dong H, Hong X, He Y, Bao Z, Zhang Y, Shen S, Wang G, Zhang J, Mo R. A carrier-free metal-organic hybrid nanoassembly with combination anti-viral and hepato-protective activity for hepatitis B treatment. Biomater Sci 2022;10:4356-66. [PMID: 35786722 DOI: 10.1039/d2bm00407k] [Reference Citation Analysis]
|
| 34 |
Woo HY, Heo J, Tak WY, Lee HJ, Chung WJ, Park JG, Park SY, Park YJ, Lee YR, Hwang JS, Kweon YO. Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial. PLoS ONE 2022;17:e0270716. [DOI: 10.1371/journal.pone.0270716] [Reference Citation Analysis]
|
| 35 |
Tong X, Song Y, Yin S, Wang J, Huang R, Wu C, Shi J, Li J. Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease. Chin Med J (Engl) 2022;135:1653-63. [PMID: 35940901 DOI: 10.1097/CM9.0000000000002310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 36 |
Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for Chronic Hepatitis B. Virulence 2022. [PMID: 35763282 DOI: 10.1080/21505594.2022.2093444] [Reference Citation Analysis]
|
| 37 |
Bahnacy A, Ghonaim M, El Hosiny EM, Gadallah AA. Occult Hepatitis (B) Infection in Hepatitis (C) Virus Infection Patients after the Treatment with Direct Acting Antiviral Drugs. Open Access Maced J Med Sci 2022;10:2529-2535. [DOI: 10.3889/oamjms.2022.7799] [Reference Citation Analysis]
|
| 38 |
Cheng X, Xia Y. HIRA in Hepatitis B Virus Minichromosome Regulation: Another Piece of the Puzzle. Cell Mol Gastroenterol Hepatol 2022;14:718-9. [PMID: 35691338 DOI: 10.1016/j.jcmgh.2022.05.009] [Reference Citation Analysis]
|
| 39 |
Peña-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, González-Praetorius A, Torralba M, Larrubia JR. Model to predict on-treatment restoration of functional HBV-specific CD8(+) cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2022;55:1545-59. [PMID: 35224746 DOI: 10.1111/apt.16850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 40 |
Magri A, Harris JM, D’arienzo V, Minisini R, Jühling F, Wing PAC, Rapetti R, Leutner M, Testoni B, Baumert TF, Zoulim F, Balfe P, Pirisi M, Mckeating JA. Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses 2022;14:1070. [DOI: 10.3390/v14051070] [Reference Citation Analysis]
|
| 41 |
Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 42 |
Ji DZ, Pang XY, Shen DT, Liu SN, Goyal H, Xu HG. Global prevalence of occult hepatitis B: A systematic review and meta-analysis. J Viral Hepat 2022;29:317-29. [PMID: 35253969 DOI: 10.1111/jvh.13660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 43 |
Wong GL, Lok AS. Chronic hepatitis B and D. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch87] [Reference Citation Analysis]
|
| 44 |
Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 45 |
Shi Z, Zheng H, Han M, Hu J, Hu Y, Li X, Zhu W, He X, Deng H, Long Q, Huang A. Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.03.003] [Reference Citation Analysis]
|
| 46 |
Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2022;42:288-98. [PMID: 34846790 DOI: 10.1111/liv.15124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Corcuera A, Donald A, Urban A. Direct‐Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection. New Drug Development for Known and Emerging Viruses 2022. [DOI: 10.1002/9783527810697.ch9] [Reference Citation Analysis]
|
| 48 |
Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, Verbinnen T, Lenz O, Talloen W, Kakuda TN, Westland C, Patel M, Yogaratnam JZ, Dragone L, Van Remoortere P. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother 2022:dkab491. [PMID: 35040959 DOI: 10.1093/jac/dkab491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 49 |
Wei J, Shi Y, Zou C, Zhang H, Peng H, Wang S, Xia L, Yang Y, Zhang X, Liu J, Zhou H, Luo M, Huang A, Wang D. Cellular Id1 inhibits hepatitis B virus transcription by interacting with the novel covalently closed circular DNA-binding protein E2F4. Int J Biol Sci 2022;18:65-81. [PMID: 34975318 DOI: 10.7150/ijbs.62106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 50 |
Calvo Sánchez H, Peña-asensio J, Larrubia Marfil JR. Current challenges in the functional cure of HBe-antigen negative chronic hepatitis B. Rev Esp Enferm Dig 2022;114. [DOI: 10.17235/reed.2022.9052/2022] [Reference Citation Analysis]
|
| 51 |
Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 52 |
Xu Z, Zhao L, Zhong Y, Zhu C, Zhao K, Teng Y, Cheng X, Chen Q, Xia Y. A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA. Cell Mol Gastroenterol Hepatol 2022;13:1001-17. [PMID: 34896285 DOI: 10.1016/j.jcmgh.2021.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 53 |
Genshaft AS, Subudhi S, Keo A, Vasquez JDS, Conceição-neto N, Mahamed D, Boeijen LL, Alatrakchi N, Oetheimer C, Vilme M, Drake R, Fleming I, Tran N, Tzouanas C, Joseph-chazan J, Villanueva MA, van de Werken HJG, van Oord GW, Groothuismink ZM, Beudeker BJ, Osmani Z, Nkongolo S, Mehrotra A, Feld J, Chung RT, de Knegt RJ, Janssen HLA, Aerssens J, Bollekens J, Hacohen N, Lauer GM, Boonstra A, Shalek AK, Gehring A. Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity.. [DOI: 10.1101/2021.11.30.470634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 54 |
Herschke F, Li C, Zhu R, Han Q, Wu Q, Lu Q, Barale-Thomas E, De Jonghe S, Lin TI, De Creus A. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms. Antiviral Res 2021;196:105196. [PMID: 34718044 DOI: 10.1016/j.antiviral.2021.105196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
De Ridder F, Sonneveld MJ, Lenz O, Janssen HLA, Talloen W, Hansen BE. Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials. J Viral Hepat 2021;28:1563-9. [PMID: 34435408 DOI: 10.1111/jvh.13599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, Slaets L, Fevery B, Smyej I, Wu LS, Li R, Siddiqui S, Oey A, Musto C, Van Remoortere P. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults. Antiviral Therapy 2021;26:58-68. [DOI: 10.1177/13596535211056581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 57 |
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med 2021;27:1725-34. [PMID: 34642494 DOI: 10.1038/s41591-021-01513-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 58 |
Asín-Prieto E, Parra-Guillen ZP, Gómez Mantilla JD, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF. A quantitative systems pharmacology model for acute viral hepatitis B. Comput Struct Biotechnol J 2021;19:4997-5007. [PMID: 34589180 DOI: 10.1016/j.csbj.2021.08.052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 59 |
Thongsri P, Pewkliang Y, Borwornpinyo S, Wongkajornsilp A, Hongeng S, Sa-Ngiamsuntorn K. Curcumin inhibited hepatitis B viral entry through NTCP binding. Sci Rep 2021;11:19125. [PMID: 34580340 DOI: 10.1038/s41598-021-98243-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 60 |
Kakuda TN, Yogaratnam JZ, Westland C, Gane EJ, Schwabe C, Vuong J, Patel M, Snoeys J, Talloen W, Lenz O, Fry J, Chanda S, van Remoortere P. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy 2021;26:13-24. [DOI: 10.1177/13596535211044331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 61 |
De Pooter D, Van Gulck E, Chen A, Evans CF, Neefs JM, Horton H, Boden D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines (Basel) 2021;9:969. [PMID: 34579206 DOI: 10.3390/vaccines9090969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Srisuwarn P, Sumethkul V. Kidney transplant from donors with hepatitis B: A challenging treatment option. World J Hepatol 2021;13:853-67. [PMID: 34552692 DOI: 10.4254/wjh.v13.i8.853] [Reference Citation Analysis]
|
| 63 |
Baudi I, Kawashima K, Isogawa M. HBV-Specific CD8+ T-Cell Tolerance in the Liver. Front Immunol 2021;12:721975. [PMID: 34421926 DOI: 10.3389/fimmu.2021.721975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 64 |
Toy M, So S, Hutton DW. Hepatitis B cure: modeling the economics of a potential cost of a cure. Curr Opin HIV AIDS 2020;15:208-12. [PMID: 32209813 DOI: 10.1097/COH.0000000000000617] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 65 |
Maepa MB, Jacobs R, van den Berg F, Arbuthnot P. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Curr Opin HIV AIDS 2020;15:200-7. [PMID: 32141890 DOI: 10.1097/COH.0000000000000623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 66 |
Kramvis A. Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa. Curr Opin HIV AIDS 2020;15:185-92. [PMID: 32141888 DOI: 10.1097/COH.0000000000000619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 67 |
Li F, Ou Q, Lai Z, Pu L, Chen X, Wang L, Sun L, Liang X, Wang Y, Xu H, Wei J, Wu F, Zhu H, Wang L. The Co-occurrence of Chronic Hepatitis B and Fibrosis Is Associated With a Decrease in Hepatic Global DNA Methylation Levels in Patients With Non-alcoholic Fatty Liver Disease. Front Genet 2021;12:671552. [PMID: 34335686 DOI: 10.3389/fgene.2021.671552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 68 |
Huang CJ, Wang LH, Wang YC. Identification of Therapeutic Targets for the Selective Killing of HBV-Positive Hepatocytes. J Pers Med 2021;11:649. [PMID: 34357116 DOI: 10.3390/jpm11070649] [Reference Citation Analysis]
|
| 69 |
Yuen MF, Zhou X, Gane E, Schwabe C, Tanwandee T, Feng S, Jin Y, Triyatni M, Lemenuel-Diot A, Cosson V, Xue Z, Kazma R, Bo Q. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol 2021;6:723-32. [PMID: 34237271 DOI: 10.1016/S2468-1253(21)00176-X] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 70 |
Li X, Xu Z, Mitra B, Wang M, Guo H, Feng Z. Elevated NTCP expression by an iPSC-derived human hepatocyte maintenance medium enhances HBV infection in NTCP-reconstituted HepG2 cells. Cell Biosci 2021;11:123. [PMID: 34225786 DOI: 10.1186/s13578-021-00641-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 71 |
Pan CQ, Li MH, Yi W, Zhang L, Lu Y, Hao HX, Wan G, Cao WH, Wang XY, Ran CP, Shen G, Wu SL, Chang M, Gao YJ, Xie Y. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int 2021;41:1498-508. [PMID: 33486874 DOI: 10.1111/liv.14801] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 72 |
Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 73 |
Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 74 |
Goyal A. Modeling reveals no direct role of the extent of HBV DNA integrations on the outcome of infection. J Theor Biol 2021;526:110793. [PMID: 34087271 DOI: 10.1016/j.jtbi.2021.110793] [Reference Citation Analysis]
|
| 75 |
Liao H, Wang J, Liu Y, Chen J, Xu D, Lu F. Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual? Hepatology 2021;73:2075-6. [PMID: 32772386 DOI: 10.1002/hep.31514] [Reference Citation Analysis]
|
| 76 |
Lee HW, Ahn SH, Chan HL. Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Semin Liver Dis 2021;41:182-90. [PMID: 33957693 DOI: 10.1055/s-0041-1723088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Kumar Dubey N, Narayan Jha G, Jana D. “COMPARATIVE EFFICACY OF ENTECAVIR AND TENOFOVIR ALAFENAMIDE IN TREATMENT OF CHRONIC HEPATITIS-B ”. ijsr 2021. [DOI: 10.36106/ijsr/2121073] [Reference Citation Analysis]
|
| 78 |
Shen Z, Gao Z, Gu C, Wu J, Wang J, Zhang J, Xie Y, Liu J. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 2021;190:105076. [PMID: 33865876 DOI: 10.1016/j.antiviral.2021.105076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 79 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 80 |
Korolowicz KE, Suresh M, Li B, Huang X, Yon C, Leng X, Kallakury BV, Tucker RD, Menne S. Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B. Viruses 2021;13:648. [PMID: 33918831 DOI: 10.3390/v13040648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 81 |
Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 82 |
Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, Miller V, Hansen BE. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:463-72. [PMID: 32473348 DOI: 10.1016/j.cgh.2020.05.041] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 83 |
Chauhan A, Kumar R, Sharma S, Mahanta M, Vayuuru SK, Nayak B, Kumar S, Shalimar. Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study. Dig Dis Sci 2021;66:873-80. [PMID: 32279172 DOI: 10.1007/s10620-020-06246-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 84 |
Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol 2021; 27(8): 666-676 [PMID: 33716446 DOI: 10.3748/wjg.v27.i8.666] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 85 |
Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK. Chronic hepatitis B: the demise of the 'inactive carrier' phase. Hepatol Int 2021;15:290-300. [PMID: 33638770 DOI: 10.1007/s12072-021-10137-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 86 |
Itokawa N, Atsukawa M, Tsubota A, Shimada N, Toyoda H, Takaguchi K, Hiraoka A, Senoh T, Koeda M, Yoshida Y, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Iwakiri K. Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B. Intern Med 2021;60:507-16. [PMID: 33583931 DOI: 10.2169/internalmedicine.5432-20] [Reference Citation Analysis]
|
| 87 |
Chan HL. Debate settled for elevated alanine aminotransferase in hepatitis B? Lancet Infect Dis 2021;21:750-1. [PMID: 33524313 DOI: 10.1016/S1473-3099(20)30682-4] [Reference Citation Analysis]
|
| 88 |
Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B. JGH Open 2021;5:34-40. [PMID: 33490611 DOI: 10.1002/jgh3.12443] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 89 |
Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 90 |
Jeng W, Lok AS. Is Cure of Hepatitis B Infection a Mission Possible? Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_20] [Reference Citation Analysis]
|
| 91 |
Huang Y, Li X, Zheng X, Tian X, Yu M, Sha L, Liu Y, Chong Y, Hao Y, You X. Bayesian network to predict hepatitis B surface antigen seroclearance in chronic hepatitis B patients. J Viral Hepat 2020;27:1326-37. [PMID: 32741055 DOI: 10.1111/jvh.13368] [Reference Citation Analysis]
|
| 92 |
Yang Y, Huang A, Zhao Y. Spontaneous loss of chronic HBV infection markers in treatment-naïve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther 2021;19:649-60. [PMID: 33164585 DOI: 10.1080/14787210.2021.1845652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 93 |
Debora Salerno, Letizia Chiodo, Vincenzo Alfano, Oceane Floriot, Grazia Cottone, Alexia Paturel, Matteo Pallocca, Marie-Laure Plissonnier, Safaa Jeddari, Laura Belloni, Mirjam Zeisel, Massimo Levrero, Francesca Guerrieri. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. Gut 2020;69. [PMID: 32114505 DOI: 10.1136/gutjnl-2019-319637] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 23.7] [Reference Citation Analysis]
|
| 94 |
Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020;17:618-34. [PMID: 32467580 DOI: 10.1038/s41575-020-0296-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 95 |
Villeret F, Zoulim F. De nouvelles cibles thérapeutiques pour la guérison de l’hépatite chronique B. Bulletin de l'Académie Nationale de Médecine 2020;204:890-899. [DOI: 10.1016/j.banm.2020.07.040] [Reference Citation Analysis]
|
| 96 |
Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. J Comp Eff Res 2020;9:1051-65. [PMID: 32945178 DOI: 10.2217/cer-2020-0068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 97 |
Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 18.3] [Reference Citation Analysis]
|
| 98 |
Binder B, Hofmann M, Thimme R. Role of Immunomodulators in Functional Cure Strategies for HBV. Curr Hepatology Rep 2020;19:337-44. [DOI: 10.1007/s11901-020-00538-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 99 |
Squires KE, Mayers DL, Bluemling GR, Kolykhalov AA, Guthrie DB, Reddy P, Mitchell DG, Saindane MT, Sticher ZM, Edpuganti V, De La Rosa A. ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother 2020;64:e00836-20. [PMID: 32540975 DOI: 10.1128/AAC.00836-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 100 |
Loomba R, Decaris M, Li KW, Shankaran M, Mohammed H, Matthews M, Richards LM, Nguyen P, Rizo E, Andrews B, Soto R, Angel T, Suri V, Kitrinos KM, Barnes D, Czerwieniec G, Brendza K, Subramanian GM, Gaggar A, Hellerstein MK. Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water Labeling. Clin Infect Dis 2019;69:542-5. [PMID: 30590481 DOI: 10.1093/cid/ciy1100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 101 |
Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, Streinu-Cercel A, Bourgeois S, Buti M, Crespo J, Manuel Pascasio J, Sarrazin C, Vanwolleghem T, Shukla U, Fry J, Yogaratnam JZ. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology 2020;159:521-533.e9. [PMID: 32343960 DOI: 10.1053/j.gastro.2020.04.036] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 102 |
Janovec V, Hodek J, Clarova K, Hofman T, Dostalik P, Fronek J, Chlupac J, Chaperot L, Durand S, Baumert TF, Pichova I, Lubyova B, Hirsch I, Weber J. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Sci Rep 2020;10:12767. [PMID: 32728070 DOI: 10.1038/s41598-020-69614-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 103 |
Gish RG, Basit SA, Ryan J, Dawood A, Protzer U. Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Curr Hepatology Rep 2020;19:254-65. [DOI: 10.1007/s11901-020-00522-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 104 |
Chua CG, Mehrotra A, Mazzulli T, Wong DK, Feld JJ, Janssen HLA, Gehring AJ. Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. Sci Rep 2020;10:11344. [PMID: 32647116 DOI: 10.1038/s41598-020-68226-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 105 |
Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 106 |
Zeng QL, Yu ZJ, Shang J, Xu GH, Sun CY, Liu N, Li CX, Lv J, Liu YM, Liang HX, Li ZQ, Pan YJ, Hu QY, Li W, Zhang DW, Wang FS. Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels. Open Forum Infect Dis 2020;7:ofaa208. [PMID: 32626791 DOI: 10.1093/ofid/ofaa208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 107 |
Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current Status of Therapy and Future Therapies. Gastroenterol Clin North Am 2020;49:215-38. [PMID: 32389360 DOI: 10.1016/j.gtc.2020.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 108 |
Slaets L, De Ridder F, Lenz O, Beumont M, Meyvisch P, Verbinnen T. Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy. GastroHep 2020;2:106-16. [DOI: 10.1002/ygh2.393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 109 |
Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. [PMID: 32450266 DOI: 10.1016/j.antiviral.2020.104824] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 110 |
Yoo SH, Kwon JH. [New Potential Therapies for Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:267-73. [PMID: 31765555 DOI: 10.4166/kjg.2019.74.5.267] [Reference Citation Analysis]
|
| 111 |
Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res 2020;179:104815. [PMID: 32380149 DOI: 10.1016/j.antiviral.2020.104815] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 112 |
Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME. Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model. J Viral Hepat 2020;27:526-36. [PMID: 31856377 DOI: 10.1111/jvh.13252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 113 |
Warner N, Locarnini S, Xu H. The role of hepatitis B surface antibodies in HBV infection, disease and clearance. Future Virology 2020;15:293-306. [DOI: 10.2217/fvl-2019-0147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 114 |
Chen MB, Wang H, Zheng QH, Cui WY, Xu HL, Zheng XW. Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2020;99:e20160. [PMID: 32384507 DOI: 10.1097/MD.0000000000020160] [Reference Citation Analysis]
|
| 115 |
Shen Z, Wu J, Gao Z, Wang J, Zhu H, Mao R, Wang X, Zhang J, Xie Y, Liu J. Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection. Theranostics 2020;10:5600-12. [PMID: 32373234 DOI: 10.7150/thno.44715] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 116 |
Berke JM, Dehertogh P, Vergauwen K, Mostmans W, Vandyck K, Raboisson P, Pauwels F. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrob Agents Chemother. 2020;64:e02439-19. [PMID: 32094138 DOI: 10.1128/aac.02439-19] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 117 |
Thom Shawa I. Hepatitis B and C Viruses. Hepatitis B and C 2020. [DOI: 10.5772/intechopen.82772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 118 |
Revill PA, Lewin SR. Editorial: Strategies and barriers for hepatitis B cure: implications for HIV. Curr Opin HIV AIDS 2020;15:151-6. [PMID: 32229770 DOI: 10.1097/COH.0000000000000620] [Reference Citation Analysis]
|
| 119 |
Liem KS, Gehring AJ, Feld JJ, Janssen HLA. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 2020;158:1185-90. [PMID: 31809724 DOI: 10.1053/j.gastro.2019.10.050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 120 |
Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res 2020;177:104783. [PMID: 32217150 DOI: 10.1016/j.antiviral.2020.104783] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 121 |
Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids. 2020;20:480-490. [PMID: 32278307 DOI: 10.1016/j.omtn.2020.03.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 122 |
Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester SV. Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure. Patient Prefer Adherence 2020;14:613-24. [PMID: 32256052 DOI: 10.2147/PPA.S238833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 123 |
Cheung KW, Lao TT. Hepatitis B - Vertical transmission and the prevention of mother-to-child transmission. Best Pract Res Clin Obstet Gynaecol 2020;68:78-88. [PMID: 32249130 DOI: 10.1016/j.bpobgyn.2020.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 124 |
Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lee HW, Lui GC, Wong VW. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int 2020;40:549-57. [PMID: 31845462 DOI: 10.1111/liv.14330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 125 |
Sbarigia U, Kariburyo F, Sah J, Colasurdo J, Xie L, Katz EG, Sylvester S. Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population. Adv Ther 2020;37:1156-72. [PMID: 32009232 DOI: 10.1007/s12325-020-01240-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 126 |
Alawad AS, Auh S, Suarez D, Ghany MG. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clin Gastroenterol Hepatol 2020;18:700-709.e3. [PMID: 31323381 DOI: 10.1016/j.cgh.2019.07.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 127 |
Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-557. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 144] [Cited by in F6Publishing: 138] [Article Influence: 48.0] [Reference Citation Analysis]
|
| 128 |
Yip TC, Lok AS. How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved? Clin Gastroenterol Hepatol 2020;18:548-50. [PMID: 31446185 DOI: 10.1016/j.cgh.2019.08.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 129 |
Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. Hepatology 2020;71:539-48. [PMID: 31309589 DOI: 10.1002/hep.30857] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 27.3] [Reference Citation Analysis]
|
| 130 |
Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 131 |
Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. IJMS 2020;21:949. [DOI: 10.3390/ijms21030949] [Cited by in Crossref: 18] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 132 |
Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: an update. Future Virology 2020;15:35-51. [DOI: 10.2217/fvl-2019-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 133 |
Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother 2020;16:251-68. [PMID: 31809638 DOI: 10.1080/21645515.2019.1689745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 134 |
Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 135 |
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2019. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 136 |
Goyal A, Liao LE, Perelson AS. Within-host mathematical models of hepatitis B virus infection: Past, present, and future. Curr Opin Syst Biol 2019;18:27-35. [PMID: 31930181 DOI: 10.1016/j.coisb.2019.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 137 |
Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol 2019;13:1065-76. [PMID: 31663387 DOI: 10.1080/17474124.2019.1686975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 138 |
Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, Schwabe C, Dunbar PR. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol 2019;71:900-7. [PMID: 31306680 DOI: 10.1016/j.jhep.2019.06.028] [Cited by in Crossref: 162] [Cited by in F6Publishing: 163] [Article Influence: 40.5] [Reference Citation Analysis]
|
| 139 |
Shi B, Wu Y, Wang C, Li X, Yu F, Wang B, Yang Z, Li J, Liang M, Wen Y, Ying T, Yuan Z. Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine 2019;49:247-57. [PMID: 31680000 DOI: 10.1016/j.ebiom.2019.10.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 140 |
Walsh R, Hammond R, Yuen L, Deerain J, O'Donnell T, Leary T, Cloherty G, Gaggar A, Kitrinos K, Subramanian M, Wong D, Locarnini S. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure. Liver Int 2019;39:2066-76. [PMID: 31379058 DOI: 10.1111/liv.14207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 141 |
Ito K. Difference between genotypes B and C in the decline and disappearance of hepatitis B surface antigen: Toward an era of direct-acting antiviral agents for hepatitis B virus. Hepatol Res 2019;49:1253-5. [PMID: 31820538 DOI: 10.1111/hepr.13456] [Reference Citation Analysis]
|
| 142 |
Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatol Commun 2020;4:8-20. [PMID: 31909352 DOI: 10.1002/hep4.1436] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 143 |
Cerino A, Mantovani S, Mele D, Oliviero B, Varchetta S, Mondelli MU. Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:2290. [PMID: 31608071 DOI: 10.3389/fimmu.2019.02290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 144 |
Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 2019;10:2308. [PMID: 31608073 DOI: 10.3389/fimmu.2019.02308] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 145 |
Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019;71:397-408. [PMID: 31004683 DOI: 10.1016/j.jhep.2019.03.034] [Cited by in Crossref: 237] [Cited by in F6Publishing: 241] [Article Influence: 59.3] [Reference Citation Analysis]
|
| 146 |
Hong T, Yang H, Kao J. Role of HBsAg Testing in the Management of Patients with Chronic HBV. Curr Hepatology Rep 2019;18:331-41. [DOI: 10.1007/s11901-019-00484-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 147 |
Inoue J, Ninomiya M, Umetsu T, Nakamura T, Kogure T, Kakazu E, Iwata T, Takai S, Sano A, Fukuda M, Watashi K, Isogawa M, Tanaka Y, Shimosegawa T, McNiven MA, Masamune A. Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production. J Virol 2019;93:e00621-19. [PMID: 31118260 DOI: 10.1128/JVI.00621-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 148 |
Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019; 25(26): 3299-3312 [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 149 |
Da BL, Surana P, Schueler SA, Jalaly NY, Kamal N, Taneja S, Vittal A, Gilman CL, Heller T, Koh C. Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease. Hepatol Commun 2019;3:1271-80. [PMID: 31497747 DOI: 10.1002/hep4.1394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 150 |
Korolowizc KE, Li B, Huang X, Yon C, Rodrigo E, Corpuz M, Plouffe DM, Kallakury BV, Suresh M, Wu TY, Miller AT, Menne S. Liver-Targeted Toll-Like Receptor 7 Agonist Combined With Entecavir Promotes a Functional Cure in the Woodchuck Model of Hepatitis B Virus. Hepatol Commun. 2019;3:1296-1310. [PMID: 31592075 DOI: 10.1002/hep4.1397] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 151 |
Charre C, Levrero M, Zoulim F, Scholtès C. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res 2019;169:104553. [PMID: 31288041 DOI: 10.1016/j.antiviral.2019.104553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 152 |
Moon IY, Choi JH, Chung JW, Jang ES, Jeong SH, Kim JW. MicroRNA20 induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells. Mol Med Rep. 2019;20:2285-2293. [PMID: 31257511 DOI: 10.3892/mmr.2019.10435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 153 |
Downs LO, Smith DA, Lumley SF, Patel M, McNaughton AL, Mokaya J, Ansari MA, Salih H, Várnai KA, Freeman O, Cripps S, Phillips J, Collier J, Woods K, Channon K, Davies J, Barnes E, Jeffery K, Matthews PC. Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. mBio 2019;10:e00699-19. [PMID: 31239374 DOI: 10.1128/mBio.00699-19] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 154 |
Qian L, Fan H, Ju Y, Chen L, Li X, Ye X, Luo Y, Li C, Meng S. A peptide-based inhibitor of gp96 suppresses HBsAg expression and HBV replication by upregulation of p53. J Gen Virol 2019;100:1241-52. [PMID: 31204972 DOI: 10.1099/jgv.0.001289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 155 |
Das S, Ramakrishnan K, Behera SK, Ganesapandian M, Xavier AS, Selvarajan S. Hepatitis B Vaccine and Immunoglobulin: Key Concepts. J Clin Transl Hepatol 2019;7:165-71. [PMID: 31293917 DOI: 10.14218/JCTH.2018.00037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 156 |
Shen Z, Liu J, Wu J, Zhu Y, Li G, Wang J, Luo M, Deng Q, Zhang J, Xie Y. IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models. Theranostics 2019;9:3798-811. [PMID: 31281514 DOI: 10.7150/thno.35331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 157 |
Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F; Members of the ICE-HBV Working Groups., ICE-HBV Stakeholders Group Chairs., ICE-HBV Senior Advisors. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019;4:545-58. [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0] [Cited by in Crossref: 223] [Cited by in F6Publishing: 231] [Article Influence: 55.8] [Reference Citation Analysis]
|
| 158 |
Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019;70:615-25. [PMID: 30529504 DOI: 10.1016/j.jhep.2018.11.030] [Cited by in Crossref: 154] [Cited by in F6Publishing: 153] [Article Influence: 38.5] [Reference Citation Analysis]
|
| 159 |
Mijočević H, Karimzadeh H, Seebach J, Usman Z, Al-Mahtab M, Bazinet M, Vaillant A, Roggendorf M. Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays. J Viral Hepat 2019;26:485-95. [PMID: 30450662 DOI: 10.1111/jvh.13044] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 160 |
Revill PA, Penicaud C, Brechot C, Zoulim F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes (Basel) 2019;10:E260. [PMID: 30939846 DOI: 10.3390/genes10040260] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 161 |
Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol 2019;70:361-70. [PMID: 30367899 DOI: 10.1016/j.jhep.2018.10.014] [Cited by in Crossref: 124] [Cited by in F6Publishing: 124] [Article Influence: 31.0] [Reference Citation Analysis]
|
| 162 |
Liang LY, Wong GL. Unmet need in chronic hepatitis B management. Clin Mol Hepatol 2019;25:172-80. [PMID: 30754963 DOI: 10.3350/cmh.2018.0106] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 163 |
Kostyushev D, Kostyusheva A, Brezgin S, Zarifyan D, Utkina A, Goptar I, Chulanov V. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Sci Rep 2019;9:1847. [PMID: 30755668 DOI: 10.1038/s41598-019-38526-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 164 |
Hsu HY, Chang MH. Hepatitis B Virus Infection and the Progress toward its Elimination. J Pediatr 2019;205:12-20. [PMID: 30244984 DOI: 10.1016/j.jpeds.2018.08.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
Locarnini S, Raimondo G. How infectious is the hepatitis B virus? Readings from the occult. Gut 2019;68:182-3. [PMID: 30068661 DOI: 10.1136/gutjnl-2018-316900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 166 |
Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodríguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, Sriprayoon T, Chong Y, Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019;156:635-646.e9. [PMID: 30342034 DOI: 10.1053/j.gastro.2018.10.027] [Cited by in Crossref: 121] [Cited by in F6Publishing: 117] [Article Influence: 30.3] [Reference Citation Analysis]
|
| 167 |
Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology 2019;156:325-37. [PMID: 30367834 DOI: 10.1053/j.gastro.2018.10.032] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 26.5] [Reference Citation Analysis]
|
| 168 |
Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat 2019;26:4-15. [PMID: 30415490 DOI: 10.1111/jvh.13040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 169 |
Kataoka H, Mochizuki T, Akihisa T, Kawasoe K, Kawachi K, Makabe S, Sawada A, Manabe S, Sato M, Amemiya N, Mitobe M, Akanuma T, Ito Y, Inoue T, Suzuki T, Matsui K, Moriyama T, Horita S, Ohara M, Honda K, Nitta K. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report. Medicine (Baltimore) 2019;98:e14014. [PMID: 30633192 DOI: 10.1097/MD.0000000000014014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 170 |
Li B, Wang Y, Shen F, Wu M, Li Y, Fang Z, Ye J, Wang L, Gao L, Yuan Z, Chen J. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen. Antimicrob Agents Chemother 2018;62:e00465-18. [PMID: 30224536 DOI: 10.1128/AAC.00465-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 171 |
Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 172 |
Liu H, Hou J, Zhang X. Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin 2018;33:459-61. [PMID: 30374825 DOI: 10.1007/s12250-018-0062-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 173 |
Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 174 |
Wang J, Chen X, Wu Y, Cao Z, Wang L, Huang H, Chen X, Lu F. Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion. Hepatol Commun 2018;2:1168-71. [PMID: 30288471 DOI: 10.1002/hep4.1249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 175 |
Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. Chin J Integr Med 2018;24:653-60. [PMID: 30209792 DOI: 10.1007/s11655-018-3011-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 176 |
Goyal A, Romero-Severson EO. Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. PLoS One 2018;13:e0203831. [PMID: 30192887 DOI: 10.1371/journal.pone.0203831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 177 |
Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis 2018;19:561-71. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 178 |
Ahn JC, Ahn J. Hepatitis B: Standard and Novel Treatment Options. Clin Liver Dis (Hoboken) 2018;12:19-23. [PMID: 30988904 DOI: 10.1002/cld.719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 179 |
Ghany MG, Block TM. Disease Pathways and Mechanisms of Potential Drug Targets. Clin Liver Dis (Hoboken) 2018;12:12-8. [PMID: 30988903 DOI: 10.1002/cld.735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 180 |
Jackson K, Locarnini S, Gish R. Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. Clin Liver Dis (Hoboken) 2018;12:5-11. [PMID: 30988902 DOI: 10.1002/cld.729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 181 |
Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol 2018; 24(31): 3488-3499 [PMID: 30131655 DOI: 10.3748/wjg.v24.i31.3488] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 182 |
Lampertico P, Berg T. Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. Hepatology 2018;68:397-400. [PMID: 29381811 DOI: 10.1002/hep.29821] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 183 |
Nevola R, Adinolfi LE, Rinaldi L. How does antiviral therapy for hepatitis B influence liver stiffness? Future Virology 2018;13:521-3. [DOI: 10.2217/fvl-2018-0076] [Reference Citation Analysis]
|
| 184 |
Corcuera A, Stolle K, Hillmer S, Seitz S, Lee JY, Bartenschlager R, Birkmann A, Urban A. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro. Antiviral Res 2018;158:135-42. [PMID: 30031759 DOI: 10.1016/j.antiviral.2018.07.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 185 |
Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 332] [Cited by in F6Publishing: 335] [Article Influence: 66.4] [Reference Citation Analysis]
|
| 186 |
Levrero M, Subic M, Villeret F, Zoulim F. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Current Opinion in Virology 2018;30:80-9. [DOI: 10.1016/j.coviro.2018.04.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 187 |
Nhu QM, Pockros PJ. Editorial: chronic hepatitis B combination therapy-emerging success as proof-of-concept for future hepatitis B eradication? Aliment Pharmacol Ther 2018;47:1560-1. [PMID: 29878430 DOI: 10.1111/apt.14680] [Reference Citation Analysis]
|
| 188 |
Tu T, Urban S. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Current Opinion in Virology 2018;30:68-79. [DOI: 10.1016/j.coviro.2018.04.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 189 |
Lee I, Yang S, Lee C, Su C, Wang Y, Lan K, Lin H, Hou M, Peng C, Huang Y. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. The Journal of Infectious Diseases 2018;218:1075-84. [DOI: 10.1093/infdis/jiy272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 190 |
Corti D, Benigni F, Shouval D. Viral envelope-specific antibodies in chronic hepatitis B virus infection. Curr Opin Virol 2018;30:48-57. [PMID: 29738926 DOI: 10.1016/j.coviro.2018.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 191 |
Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319:1802-13. [PMID: 29715359 DOI: 10.1001/jama.2018.3795] [Cited by in Crossref: 359] [Cited by in F6Publishing: 322] [Article Influence: 71.8] [Reference Citation Analysis]
|
| 192 |
Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. Front Microbiol 2018;9:662. [PMID: 29675010 DOI: 10.3389/fmicb.2018.00662] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 193 |
Dusheiko G. Current and future directions of management of hepatitis B: steps toward a cure. Future Virology 2018;13:189-209. [DOI: 10.2217/fvl-2017-0103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 194 |
Germanidis G, Hytiroglou P, Vassiliadis T, Speletas M. Checkpoint modulation in chronic hepatitis B: From hypothesis to approval. Hepatology 2018;67:1175-6. [PMID: 29194685 DOI: 10.1002/hep.29695] [Reference Citation Analysis]
|
| 195 |
Sherman KE, Shah VH. Viral Hepatitis: Knowledge and Treatments for Hepatitis B and C Virus and Associated Transplantation and Neoplasia. Gastroenterology 2018;154:453-6. [PMID: 29154778 DOI: 10.1053/j.gastro.2017.10.047] [Reference Citation Analysis]
|
| 196 |
Ma Z, Cao Q, Xiong Y, Zhang E, Lu M. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines (Basel) 2018;6:E6. [PMID: 29337856 DOI: 10.3390/vaccines6010006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 197 |
Rinaldi L, Ascione A, Messina V, Rosato V, Valente G, Sangiovanni V, Zampino R, Marrone A, Fontanella L, de Rosa N, Orabona P, Buonomo C, Chirianni A, Adinolfi LE, Piai G. Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection 2018;46:231-8. [PMID: 29335905 DOI: 10.1007/s15010-017-1113-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
